JAK Inhibitors in Inflammatory Bowel Disease: Mechanism, Indications, and Safety Considerations
Muhammad Waqas, Ex Resident Pharmacist at Shifa International Hospitals Limited, shared on LinkedIn:
“๐๐๐ ๐๐ป๐ต๐ถ๐ฏ๐ถ๐๐ผ๐ฟ๐ ๐ถ๐ป ๐๐๐
1. Mechanism of Action: Janus kinase (JAK) inhibitors block intracellular JAK-STAT signaling,reduces cytokine-driven inflammation. They are oral small molecules (unlike biologics) and act on multiple cytokine pathways.
๐ฎ. ๐๐ฝ๐ฝ๐ฟ๐ผ๐๐ฒ๐ฑ ๐๐๐ ๐๐ป๐ต๐ถ๐ฏ๐ถ๐๐ผ๐ฟ๐
Tofacitinib: Oral, non-selective JAK1/3 inhibitor
Upadacitinib: Oral, selective JAK1 inhibitor
Filgotinib Oral, selective JAK1 inhibitor
Peficitinib Investigational / clinical trials JAK1/3 inhibitor
3. Indications / Patient Selection
โข Moderate-to-severe UC failing:
โข Corticosteroids
โข Immunomodulators (azathioprine, 6-MP)
โข Biologics (biologic-refractory disease.)
โข Useful for patients preferring oral therapy
๐ฐ. ๐๐ผ๐๐ถ๐ป๐ด (๐ฒ๐
๐ฎ๐บ๐ฝ๐น๐ฒ)
โข ๐ง๐ผ๐ณ๐ฎ๐ฐ๐ถ๐๐ถ๐ป๐ถ๐ฏ:
โข ๐๐ป๐ฑ๐๐ฐ๐๐ถ๐ผ๐ป: ๐ญ๐ฌ ๐บ๐ด ๐ผ๐ฟ๐ฎ๐น๐น๐ ๐๐๐ ๐ณ๐ผ๐ฟ ๐ด ๐๐ฒ๐ฒ๐ธ๐
โข ๐ ๐ฎ๐ถ๐ป๐๐ฒ๐ป๐ฎ๐ป๐ฐ๐ฒ: ๐ฑโ๐ญ๐ฌ ๐บ๐ด ๐๐๐ (๐ฏ๐ฎ๐๐ฒ๐ฑ ๐ผ๐ป ๐ฟ๐ฒ๐๐ฝ๐ผ๐ป๐๐ฒ)
โข ๐จ๐ฝ๐ฎ๐ฑ๐ฎ๐ฐ๐ถ๐๐ถ๐ป๐ถ๐ฏ:
โข ๐๐ป๐ฑ๐๐ฐ๐๐ถ๐ผ๐ป: ๐ฐ๐ฑ ๐บ๐ด ๐ฑ๐ฎ๐ถ๐น๐
โข ๐ ๐ฎ๐ถ๐ป๐๐ฒ๐ป๐ฎ๐ป๐ฐ๐ฒ: ๐ญ๐ฑโ๐ฏ๐ฌ ๐บ๐ด ๐ฑ๐ฎ๐ถ๐น๐
๐ฑ. ๐๐ฑ๐๐ฒ๐ฟ๐๐ฒ ๐๐ณ๐ณ๐ฒ๐ฐ๐๐ / ๐ฆ๐ฎ๐ณ๐ฒ๐๐
โข Infections: Herpes zoster, serious bacterial/fungal infections
โข Thrombosis risk: Deep vein thrombosis, pulmonary embolism (especially at higher doses or risk factors)
โข Lipid abnormalities: โ LDL, โ HDL
โข Hematologic: Anemia, leukopenia, lymphopenia
โข Other: GI perforation (rare), elevated liver enzymes
๐ฒ. ๐ ๐ผ๐ป๐ถ๐๐ผ๐ฟ๐ถ๐ป๐ด
โข Baseline: CBC, LFTs, lipid profile, TB and hepatitis screening
โข Ongoing: CBC, LFTs, lipid profile periodically; monitor for infections”
Read more on Hemostasis Today.
-
Nov 8, 2025, 05:31Phenotyping of Human Platelets by Daisie Yates
-
Nov 8, 2025, 04:35Inaugural Women In Hematology US Focus Meeting 2025 Officially Commenced
-
Nov 7, 2025, 06:59Stephen Cornelissen is Celebrating an Extraordinary Milestone at Australian Red Cross Lifeblood
-
Nov 7, 2025, 06:56Reza Shojaei on Leadership in the Blood and Plasma Sector
-
Nov 7, 2025, 06:52Rachel Margolis-Goodman Announces Groundbreaking Expension of Versiti Blood Research Institute
-
Nov 7, 2025, 06:46What’s New in HIT from THANZ Webinar Series
-
Nov 7, 2025, 03:30Abdallah Othman About Cardiac Vasculatureย
-
Nov 7, 2025, 03:29Aabha Divya: Thrilled to Share Our Latest Publication inย Annals of Thoracic Surgery Short Reports!
-
Nov 7, 2025, 03:28Shantel Holcomb: Boston Scientific is Investing in Innovative Solutions to Improve Outcomes for Patients With CAD